Wordt geladen...
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as...
Bewaard in:
| Gepubliceerd in: | Cancers (Basel) |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6210751/ https://ncbi.nlm.nih.gov/pubmed/30241301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10100342 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|